Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Dutton Associates Featured Company: Pluristem Therapeutics, Inc. (PSTI)

Pluristem Therapeutics, Inc. (NASDAQ: PSTI) is a regenerative biotherapeutics corporation focused on commercializing non-personalized (allogeneic) stem cell therapy products for the treatment of severe degenerative, malignant, and autoimmune disorders. The company is dedicated to developing a platform designed to create stem cell-based therapeutic products that can treat severe blood, cardiovascular, autoimmune, and other disorders.

The company is currently developing the PluriX™ 3D Bioreactor System, which is designed to create an artificial physiological environment where mesenchymal stem cells can expand in three dimensions and reproduce without the use of exogenous biologics or pharmacological products. This new method is superior to the traditional method of MSC expansion that uses standard, two-dimensional cell culture techniques in conjunction with fetal bovine serum, growth factors, and leukemia inhibitory factor.

Pluristem’s products are obtained from mesenchymal stromal cells found in the placenta—not from controversial embryonic stem cells—and are stored in a readily available state for patient use. The company anticipates that this new technology has the potential to partake of the approximately $30-billion therapeutic and regenerative cellular industries.

Let us hear your thoughts: Pluristem Therapeutics, Inc. Message Board

Posted in Dutton Associates, Pluristem Therapeutics Inc. PSTI | No Comments »
Dutton Associates Featured Company: Pressure BioSciences, Inc. (PBIO)
Thursday, July 10th, 2008

Pressure BioSciences, Inc. (PBIO) is focused on developing products based on its proprietary pressure cycling technology (PCT) for life-sciences applications. The innovative technology utilizes hydrostatic pressure, which cycles between ambient and ultra-high levels, to rapidly and proficiently disrupt cell membranes/tissues to remove nucleic acids, proteins, and small molecules from plant and animal materials.

The PCT technology has a broad range of possible applications in genomics and proteomics, in addition to drug discovery, pathogen inactivation, food safety, immunodiagnostics, and DNA sequencing. Currently, the PCT System consists of a top-of-the-line instrument and disposable PULSE sample processing tubes. Pressure BioSciences plans to develop other instrumentation and disposables to meet additional needs in life sciences’ laboratories.

The company’s proprietary technology addresses the number-one issue in sample preparation that creates significant bottlenecks in research. Existing technology does not produce consistent results, requires multiple steps, and has a high risk of contamination. By utilizing Pressure BioSciences’ PCT technology, researchers can achieve much better results in a single-step process.

The CEO and president of Pressure BioSciences, Mr. Richard T. Schumacher, founded the company in 1978 as Boston Biomedica, which later became known as Pressure BioSciences in 2004. He has extensive experience in the medical field, helped build Panacos Pharmaceuticals into a public company valued at more than $200 million, and guided Boston Biomedica from a start-up company to realizing $30 million in sales as Pressure BioSciences.

Let us hear your thoughts: Pressure BioSciences, Inc. Message Board

This entry was posted in Small Cap News. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *